Localized prostate cancer: to treat or to watch
The hardest part isn't treating prostate cancer — it's deciding which ones to leave alone. Active surveillance for the indolent, surgery or radiation for the rest, and a long conversation about continence and erections that matters as much as the cancer math.
The one-liner
Risk-stratify (PSA, ISUP grade, stage), then match intensity: active surveillance for low-risk, RP or radiation ± ADT for intermediate/high-risk. ProtecT showed surgery and radiation are equivalent for survival in localized disease — so the decision turns on side-effect profiles and the patient's values.
Localized prostate cancer is the disease where doing less is often the harder, braver call. Many of these cancers grow so slowly that the man will die with them, not ofthem — and the treatments, for all their precision, exact a real toll in continence and erections. The whole discipline is matching the aggressiveness of the treatment to the aggressiveness of the cancer, and then to the man’s own priorities.
Risk stratification is the fork in the road
Three inputs — PSA, ISUP grade group, and clinical T stage— sort men into broad risk bands (the D’Amico/NCCN logic):
- Low risk— PSA < 10, grade group 1, ≤ cT2a.
- Intermediate risk— PSA 10–20, grade group 2–3, or cT2b–c.
- High risk— PSA > 20, grade group 4–5, or ≥ cT3.
Active surveillance: treating the patient, not the biopsy
For low-risk disease (and selected favorable intermediate-risk, grade group 2), the standard of care is active surveillance — not neglect, but structured monitoring with serial PSA, periodic mpMRI, and repeat biopsy, with a plan to treat if the cancer shows it is upgrading. The point is to spare men the side effects of treatment for a cancer that may never threaten them, while keeping a curative window open.
What everyone gets wrong
Framing surveillance as “watchful waiting” or doing nothing. Active surveillance is active — it has a protocol and a trigger to intervene. Watchful waiting is a different thing entirely: symptom-directed, non-curative management for men whose life expectancy or comorbidity means cure was never the goal. Conflating the two frightens patients out of the right choice.
The two curative paths — and the trial that made them equal
For disease that warrants treatment, the two mainstays are surgery and radiation:
- Radical prostatectomy — removal of the prostate and seminal vesicles, increasingly robot-assisted, with nerve-sparing where oncologically safe. Gives definitive pathology and a clean PSA endpoint.
- External beam radiotherapy — typically 76–80 Gy in fractions, often with androgen deprivationadded for intermediate (short-course, ~4–6 months) and high-risk disease (long-course, 18–36 months).
- Brachytherapy — radioactive seeds (LDR) or temporary high-dose-rate sources, alone for low-risk or as a boost.
ProtecT randomized localized prostate cancer to surgery, radiation, or monitoring — and at long follow-up, cancer-specific survival was the same across all three. The cancer rarely decides; the side effects do.
Because survival is equivalent for localized disease, the real decision turns on the side-effect profiles: surgery front-loads incontinence and erectile dysfunction that then recover over months; radiation tends to spare early continence but brings irritative urinary and bowel symptomsand a slower, later decline in erections. The right answer is the one that fits the man’s life.
Reading the aftermath: biochemical recurrence
PSA is the perfect tumor marker after treatment because, with the prostate gone or ablated, it should fall and stay down. A rise signals recurrence — but the definition depends on the treatment:
- After radical prostatectomy — PSA ≥ 0.2 ng/mL, confirmed on a second reading.
- After radiotherapy — the Phoenix definition: a rise of ≥ 2 ng/mL above the nadir.
A recurrence triggers restaging (PSMA-PET) and a salvage discussion — salvage radiation after surgery, or salvage local therapy ± ADT after radiation.
If you remember one thing
Localized prostate cancer is a decision before it is a procedure. Risk-stratify honestly, surveil the indolent ones without apology, and when treatment is warranted, remember ProtecT: surgery and radiation cure equally, so let the man choose the side effects he can live with.